Novartis AG (NYSE:NVS) Given Consensus Rating of “Hold” by Analysts

Novartis AG (NYSE:NVS) has been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $93.34.

Several brokerages have recently commented on NVS. ValuEngine upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research report on Saturday, October 19th. Cowen restated a “buy” rating and set a $100.00 target price on shares of Novartis in a research note on Friday, October 25th.

Novartis stock traded up $0.36 during midday trading on Thursday, hitting $94.96. The stock had a trading volume of 105,895 shares, compared to its average volume of 1,078,199. Novartis has a 52-week low of $74.70 and a 52-week high of $95.66. The company has a market capitalization of $216.80 billion, a PE ratio of 18.66, a P/E/G ratio of 1.95 and a beta of 0.59. The firm’s fifty day moving average is $93.65 and its two-hundred day moving average is $90.24. The company has a current ratio of 0.95, a quick ratio of 0.73 and a debt-to-equity ratio of 0.42.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 22nd. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.10. The business had revenue of $12.17 billion for the quarter, compared to the consensus estimate of $11.67 billion. Novartis had a net margin of 24.43% and a return on equity of 20.86%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.32 earnings per share. As a group, equities research analysts predict that Novartis will post 5.23 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of NVS. Grimes & Company Inc. raised its holdings in shares of Novartis by 1.8% during the 3rd quarter. Grimes & Company Inc. now owns 67,722 shares of the company’s stock worth $5,885,000 after acquiring an additional 1,170 shares in the last quarter. Bangor Savings Bank purchased a new position in shares of Novartis in the 3rd quarter worth $212,000. Kovack Advisors Inc. purchased a new position in shares of Novartis in the 3rd quarter worth $375,000. Creative Planning increased its holdings in shares of Novartis by 0.4% in the 3rd quarter. Creative Planning now owns 73,993 shares of the company’s stock worth $6,430,000 after buying an additional 328 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of Novartis by 41.0% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 7,444 shares of the company’s stock worth $647,000 after buying an additional 2,164 shares during the last quarter. Hedge funds and other institutional investors own 10.62% of the company’s stock.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Further Reading: What is a Call Option?

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.